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Abstract
Objective
To delineate the natural history, diagnosis, and treatment response of Parkinson disease (PD) in individuals with
22q11.2 deletion syndrome (22q11.2DS), and to determine if these patients diﬀer from those with idiopathic PD.
Methods
In this international observational study, we characterized the clinical and neuroimaging features of 45 indi-
viduals with 22q11.2DS and PD (mean follow-up 7.5 ± 4.1 years).
Results
22q11.2DS PD had a typical male excess (32 male, 71.1%), presentation and progression of hallmark motor
symptoms, reduced striatal dopamine transporter binding with molecular imaging, and initial positive response to
levodopa (93.3%). Mean age at motor symptom onset was relatively young (39.5 ± 8.5 years); 71.4% of cases had
early-onset PD (<45 years). Despite having a similar age at onset, the diagnosis of PDwas delayed in patients with
a history of antipsychotic treatment compared with antipsychotic-naive patients (median 5 vs 1 year, p = 0.001).
Preexisting psychotic disorders (24.5%) and mood or anxiety disorders (31.1%) were common, as were early
dystonia (19.4%) and a history of seizures (33.3%).
Conclusions
Major clinical characteristics and response to standard treatments appear comparable in 22q11.2DS-associated
PD to those in idiopathic PD, although the average age at onset is earlier. Importantly, treatment of preexisting
psychotic illness may delay diagnosis of PD in 22q11.DS patients. An index of suspicion and vigilance for
complex comorbidity may assist in identifying patients to prioritize for genetic testing.
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Parkinson disease (PD) is a complex neurodegenerative
disorder. While many genetic factors have been identiﬁed
that increase the risk to develop the disease,1 genetic testing
is not part of general clinical practice.2 A recently discovered
genetic risk factor, accounting for approximately 0.5% of
patients with early-onset PD (EOPD), is the recurrent
hemizygous 22q11.2 deletion associated with 22q11.2
deletion syndrome (22q11.2DS).3,4 Previously known as
DiGeorge or velocardiofacial syndrome, 22q11.2DS is an
underdiagnosed multisystem genetic condition that can in-
clude birth defects, intellectual and developmental disabilities,
seizures, psychotic disorders, and endocrine abnormalities. The
associated 22q11.2 deletion, detectable on clinical genetic
testing, is estimated to be present in 1 in 3,000 live births.5
Although multiple case reports and 2 case series have been
important in discovering the connection between PD and
22q11.2 deletions, and neuropathologic examination has
shown classic loss of midbrain dopaminergic neurons with
variable Lewy body pathology,3 it is essential to compile
a larger sample with more comprehensive data to understand
how this genetic subtype may be similar to—or diﬀerent
from—typical idiopathic PD and other genetic forms of PD.
We therefore obtained clinical and neuroimaging data from
physicians for all identiﬁed 22q11.2DS PD cases around the
world, in order to delineate the natural history, diagnosis,
and treatment response of this genetic subtype of PD. The
results indicate that, while many features are similar to those
of typical PD, an increased index of suspicion together with
clinical clues from the patient’s history may help prompt
genetic testing for 22q11.2 deletion and prevent delayed
diagnosis of PD.
Methods
Identification and characterization of cases
We obtained clinical and neuroimaging data for 45 individuals
with 22q11.2DS who met the inclusion criteria for this study:
a molecularly conﬁrmed 22q11.2 deletion involving the typi-
cally deleted region and PD deﬁned as a clinical diagnosis by
a neurologist,2,5 including bradykinesia and at least one of either
rest tremor or rigidity. We excluded individuals deemed to have
drug-induced parkinsonism or parkinsonism of unknown etiol-
ogy.6We used the standard EOPD deﬁnition of age at onset <45
years.2 We used comprehensive data forms to systematically
collect anonymized clinical data on each patient with PD and
22q11.2DS (see appendix e-1, links.lww.com/WNL/A515);
these were completed by the participating physicians using
medical records or direct assessment for 26 (74.3%) of 35 pre-
viously reported cases identiﬁed through an extensive
literature review and 10 unpublished cases identiﬁed through the
International Consortium on Brain and Behavior in 22q11.2DS,
a Canadian adult cohort, and personal communications (ﬁgure 1
[study ﬂow chart]; table e-1, links.lww.com/WNL/A513 [pub-
lished cases with PD and 22q11.2DS]; and appendix e-2 [results
of literature search]).
Standard protocol approvals, registrations,
and patient consents
The requirement for informed consent for this retrospective
study diﬀered between participating countries; informed con-
sent was obtained if required.
Statistical analyses
Statistical analyses were conducted using IBM SPSS Statistics 22
forWindows (SPSS Inc., Chicago, IL).We used an independent-
samples t test or Mann-WhitneyU test to investigate diﬀerences
in age at motor symptom onset, age at PD diagnosis, and time to
clinically conﬁrmed PDdiagnosis, inmale vs female patients, and
in antipsychotic-naive patients vs those taking antipsychotic
medication, as appropriate. We used the McNemar test to de-
termine if there was an increase in prevalence of motor symp-
toms over the course of PD.We used a binary logistic regression
analysis to investigate the association between sex and history of
antipsychotic medication use and the presence of motor symp-
toms at presentation, and the association between sex and
follow-up time and the prevalence of motor symptoms over the
course of PD. All analyses were 2-tailed, with statistical signiﬁ-
cance deﬁned as p < 0.05. We excluded cases missing values on
a particular outcome for that analysis.
Data availability
Anonymized data will be shared by request from any qualiﬁed
investigator, only for purposes of replicating procedures and
results.
Results
Diagnosis of 22q11.2DS, family history of PD,
and other genetic factors
Patients tended to have a late diagnosis of the 22q11.2 deletion
(mean age 40.2 ± 13.0 years, n = 38), with the genetic diagnosis
in more cases occurring after (n = 24 [63.1%]) than before (n =
12 [31.6%]) PD motor symptom onset (n = 2 age at onset
unknown). With respect to associated developmental features,
therewere just 11 (24.4%) patients with a congenital heart defect
reported but 28 (62.2%) with intellectual disability, most in the
mild range (table e-2, links.lww.com/WNL/A513).
As expected,5 most cases with information on inheritance
status had a de novo 22q11.2 deletion (n = 16 of 19 [84.2%]).
Glossary
22q11.2DS = 22q11.2 deletion syndrome; DAT = dopamine transporter; EOPD = early-onset Parkinson disease; PD =
Parkinson disease.
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Three had maternally inherited deletions, including one rare
mosaic deletion. Two female patients had an additional ge-
netic ﬁnding of possible clinical relevance: 45,X[3]/46,XX[7]
mosaic Turner syndrome, and a maternally inherited 3q29
duplication with unknown pathogenicity, respectively. Wilson
disease was considered, but ruled out, in 2 male patients (at
ages 30 and 46 years, respectively).
There were 4 cases (8.9%) reported to have a parent with
PD: 1 where the parent had EOPD (31 years); 1 other also
had 3 paternal second-degree relatives with a history of
PD (1 with onset <50 years). A ﬁfth patient had a brother
with amyotrophic lateral sclerosis. The inheritance status
of the 22q11.2 deletion was unknown in all of these 5 cases.
Genetic testing was performed for known PD genes using
various strategies for 17 patients, including 2 of the 5 with
family history of neurodegenerative disease.3,4 The only
ﬁnding was a missense mutation (HTRA2 p.G399S) of
uncertain relevance to PD, inherited from an unaﬀected
mother.7
Sex distribution, age at motor symptom onset,
and PD diagnosis
Of 45 individuals with 22q11.2DS-associated PD, 32 (71.1%)
were male, indicating a typical PD sex distribution.8 Onset
was early in 22q11.2DS-associated PD, as expected.3,4,9 For
the 35 (81.4%) cases with data available, mean age at onset
of motor symptoms was 39.5 ± 8.5 years, and 25 (71.4%)
met EOPD criteria. Motor symptom onset on average was
2 years later in women, a nonsigniﬁcant sex diﬀerence
(women [40.9 ± 8.2 years, n = 11], men [38.8 ± 8.7 years,
n = 24]; p = 0.51). The mean age at PD diagnosis was 42.1 ±
9.0 years (n = 38 [88.4%]) with no signiﬁcant sex diﬀerence
(p = 0.30).
Figure 1 Study flow chart: Identification and characterization of patients with 22q11.2 deletion syndrome and Parkinson
disease
a Literature review performed on November 1, 2016. b One publication by our own group. c Two cases were reported during preparation of this article.16,31
22q11.2DS IBBC = International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.
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Despite having similar ages at median motor symptom onset,
individuals with a history of antipsychotic use had a longer
median time to PD diagnosis (5, range 0–14 years) than
antipsychotic-naive patients (1, range 0–7 years; p= 0.001, ﬁgure
2). Although clozapine is not expected to cause parkinsonism,2
there were 2 patients with a time to PD diagnosis of 9 years, on
clozapine monotherapy for most of that time period.
Motor symptoms, response to treatment,
and mortality
Table 1 shows data available on motor symptoms in the onset
year and at last assessment. For those with distribution of
motor symptom onset documented (n = 30), the majority had
asymmetric onset, including 20 of 22 (90.9%) antipsychotic-
naive cases and 7 of 8 (87.5%) antipsychotic-exposed cases. A
less typical ﬁnding at presentation was dystonia (table 1).10
Neither sex nor history of antipsychotic medication use
appeared to aﬀect the presence of motor symptoms.
There was evidence of progression of motor symptoms
over the course of PD with worsening for all typical features
of PD except writing/loss of dexterity, where results were at
the trend level (table 1). Neither presence of dystonia nor
dyskinesia at last assessment was associated with sex or
duration of follow-up (data not shown). Dyskinesia, how-
ever, was less likely to emerge with PD progression in
women than men (odds ratio 0.10, 95% conﬁdence interval
0.01–0.91; p = 0.04).
Most patients received typical PD treatments (table e-3, links.
lww.com/WNL/A513) with response reported as positive
(table 2). Polypharmacy and deep brain stimulation were
fairly common (table 2).
Seven patients had died, 3 of whom met EOPD criteria.
Median age at death was 56 years (range 42–61) after a me-
dian time from onset of motor symptoms of 9 years (5–18)
for the 6 patients with data. There were only 3 patients with
known cause of death: pneumonia (n = 2) and cardiac failure
(n = 1).
Neurological and psychiatric symptoms
Before PD onset, there were 11 (24.4%) patients with a his-
tory of a psychotic disorder, and 14 (31.1%) with mood or
anxiety disorder, in line with expectations for adults with
22q11.2DS.11,12 Fifteen (33.3%) patients had a lifetime his-
tory of seizures, a somewhat greater proportion than in a re-
cent survey of 22q11.2DS (15.8%).13
With progression of PD, symptoms of psychosis, anxiety, or
depression emerged in 7 (20.6%), 6 (17.6%), and 6 (18.2%)
patients with no history of these, respectively. Emergence
of cognitive decline was reported in 8 (17.8%) cases. Other
emerging symptoms included impulse control disorders (n = 6),
emotional lability (n = 3), altered sleep or eating habits (n = 3),
confusion (n= 1), and self-injurious behavior (n = 1). Emergence
of psychiatric symptomswith progression of PDwas attributed to
antiparkinsonian medication in 8 patients. There were only 10
(22.2%) cases with no known history of any lifetime neuropsy-
chiatric disorder or symptoms at last assessment or death.
Dopaminergic imaging
Twenty (44.4%) patients had presynaptic dopaminergic imaging
results available. Of 18 patients with dopamine transporter
(DAT) SPECT imaging results, 17 showed typical ﬁndings of
reduced (contralateral or bilateral) striatal binding.4,9,14,15 This
included 6 (33.3%) patients taking antipsychotic medication.
Figure 2 Antipsychotic medication and delay in diagnosis of Parkinson disease (PD) in 22q11.2 deletion syndrome
*Complete data on age atmotor symptom onset, age at PD diagnosis, and history of antipsychoticmedication use were available for 33 cases (for n = 8 cases,
antipsychotic status was uncertain). Two suspected PD cases receiving antipsychotic medication (see e-Methods, links.lww.com/WNL/A514) were excluded.
(A) There was no difference in mean age at motor symptom onset (38.7 ± 8.9 vs 40.6 ± 6.9 years) between patients without and patients with a history of
antipsychotic use. (B) However, themedian time betweenmotor symptom onset and a diagnosis of PDwas shorter in antipsychotic-naive patients compared
to thosewith a history of antipsychotic treatment. Triangle without fill = in the antipsychotic-naive group, the patient with the youngest age atmotor symptom
onset (18 years) had the longest time to diagnosis. Also, in this patient with reduced dopamine transporter (DAT) binding on imaging, bradykinesia could not
be established formally due to cognitive impairment. Diamonds without fill = patients using clozapine before PD diagnosis. Diamond with black fill = in one
patient, the neurologist deferred the PDdiagnosis due to olanzapine use. Fourteen years after the onset ofmotor symptoms, DAT imaging showed the typical
pattern of severely reduced striatal DAT binding. EOPD = early-onset (<45 years) PD.
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One of the 18 patients showed a marked loss of striatal DATs in
the ipsilateral putamen, and a slight reduction in binding in the
contralateral caudate nucleus.
Two patients had data from a scientiﬁc study using PET and
11C-dihydrotetrabenazine ([11C]DTBZ), a radioligand that
binds to the presynaptic vesicular monoamine transporter 2.16
One patient showed the typical pattern of severely reduced
striatal [11C]DTBZ binding.16The patient with the next lowest
striatal binding levels among the patients with 22q11.2DS
studied, in the lower range of that for the healthy control group,
was a 55-year-old man with parkinsonism.6,16–18 He sub-
sequently had further decline in motor and cognitive func-
tioning, and at age 57 years, demonstrated an unequivocal
improvement in motor symptoms following levodopa treat-
ment, and was deemed to meet criteria for PD.
Discussion
This international collaborative study is the largest to date on
22q11.2DS-associated PD, providing new data on the clinical
presentation, progression, and treatment response. The results
(summarized in table 3) suggest that a male excess and the main
clinical features of PD, including response to levodopa with de-
velopment of dyskinesia in a high proportion of patients, would
be indistinguishable from idiopathic PD.8,19 The majority of the
cases met EOPD criteria. We note however that given a median
age at death in 22q11.2DS in the mid-40s,20 many patients may
not live long enough to develop PD. Congenital or other later
onset features could prompt clinicians to consider genetic testing
for the 22q11.2 deletion, especially in individuals with early-onset
PD, early dystonia, a history of seizures, and neurodevelopmental
disorders such as schizophrenia or intellectual disability.
Patients exposed to antipsychotic treatment were diagnosed
with PD later than antipsychotic-naive patients, despite the
fact that few had symmetric parkinsonism.21 Some have
proposed that nonmotor features including fatigue and
hyposmia could help distinguish betweenmedication-induced
parkinsonism and PD.22 However, we did not assess these
features in this study and believe them unlikely to be helpful as
they are common manifestations of 22q11.2DS itself.16,23,24
The DAT imaging ﬁndings suggest that dopaminergic imag-
ing, where available, may be helpful in the diﬀerentiation of
PD from nondegenerative 22q11.2DS-related parkinson-
ism.25 This is particularly important when one considers that
;25% of 22q11.2DS patients will need antipsychotic treat-
ment.26 Potentially complicating the interpretation of imaging
results for individuals with 22q11.2DS, however, are obser-
vations of paradoxical elevated striatal [11C]DTBZ and [18]F-
PRO4.MZ (a DAT ligand) binding levels in some adults.16
This emphasizes the need for longitudinal imaging studies,
Table 1 Motor symptom features and progression of Parkinson disease (PD) in 36 patients with 22q11.2 deletion
syndrome
Motor symptoms typical of PD
At initial presentation of
motor symptoms
At last assessment (mean 7.5 ± 4.1 years after
onset of motor symptoms)
p Valuen % n %
Symptoms used for diagnosis of PD
Bradykinesiaa 24 66.7 35 97.2 0.002
Muscle stiffness/rigidity/reduced arm swing 25 63.9 36 100.0 0.001
Tremorb 29 80.6 35 97.2 0.03
Other typical features of PD
Dyskinesiac 1 2.8 16 44.4 <0.0001
Falls or assistance needed with ambulation 1 2.8 17 47.2 <0.0001
Postural instability 4 11.1 19 52.8 <0.0001
Gait changes 11 30.6 24 66.7 <0.001
Swallowing disturbances worsened from baseline 3 8.3 13 36.1 0.002
Change in writing/loss of dexterity 15 41.7 19 52.8 0.06
Other motor symptoms
Dystoniad 7 19.4 15 41.7 0.008
Data on motor symptoms (in year of initial presentation and with progression in PD) and on follow-up time was available for 36 cases (26 male, 72.2%).
a Bradykinesia could not be established formally in one patient (with tremor and rigidity) due to cognitive impairment.
b Rest tremor was reported in 28 of 36 (77.8%) cases at last assessment. In 4 cases (11.1%), the tremor type was not specified.
cDyskinesia was associated with antiparkinsonian medication in the vast majority of cases; see table 2 for correlation with levodopa use.
d Five of the 7 cases with dystonia in the year of initial PD presentation were antipsychotic-naive.
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and neuropathologic studies, to help delineate the dopami-
nergic mechanisms and trajectory of 22q11.2DS.27
Neuropsychiatric disorders are common features in
22q11.2DS.11 Nevertheless, a signiﬁcant proportion of the
patients in this study demonstrated emergence of psychotic
symptoms with progression of PD. It remains unclear to what
extent symptoms such as cognitive decline, psychosis, anxiety,
and depression are due to PD,28,29 the 22q11.2 deletion,26 and/or
eﬀects of antiparkinsonian medications. Given the complex
neuropsychiatric expression, including intellectual disability,
other movement disorders,6,16 and the multisystem nature of
22q11.2DS,5,26 optimal management of 22q11.2DS-
associated PD would involve collaboration between a move-
ment disorders neurologist and specialist in 22q11.2DS.
If a 22q11.2 deletion is suspected, standard clinical micro-
arrays will detect this structural change.5 It is important to
realize that currently available PD genetic diagnostic panels
do not include the 22q11.2 deletion. However, as for other
PD-related mutations, much remains to be known about
interacting factors that may contribute to the risk for PD
imparted by a 22q11.2 deletion.30 Absence of an aﬀected
relative would not aﬀect decision-making for genetic testing;
the 22q11.2 deletion occurs as a spontaneous (de novo)
mutation in most individuals.30
The strengths of the study include the collaborative nature of
the work and the large number of patients, given that both
EOPD and 22q11.2DS are relatively uncommon conditions.
There were, however, several limitations. First, we acknowl-
edge the lack of a typical PD comparison group. Second,
publication bias has to be considered. For example, it is
conceivable that patients with less typical PD or uncertain PD
diagnosis, yet with true PD, are underrepresented. Third, it
cannot be ruled out that handling of conﬂicting, ambiguous,
missing, or unknown data may have inﬂuenced the study
results. Fourth, survey responders may have interpreted def-
initions of variables diﬀerently. Fifth, there was a wide range of
follow-up time from 0 to 21 years. Sixth, physicians did not
systematically obtain clinical information on non-neurologic
comorbidities; therefore we opted not to report on other
22q11.2DS-associated comorbidities (table e-2, links.lww.
com/WNL/A513) in this study.
Further prospective clinical, neuropathologic, molecular, and
animal studies promise to help clarify the pathogenesis of this
molecular subtype of PD and indicate how well 22q11.2DS-
PD could act as a genetic model for other forms of PD.
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Table 2 Response to treatment in patients with 22q11.2
deletion syndrome–associated Parkinson
disease
Reported
for, n
Positive
response, n
Antiparkinsonian
medications
Levodopaa 30 28 (93.3%)b
Dopamine agonistc 14 12 (85.7%)d
Anticholinergic 3 2
MAO-B inhibitor 3 3
COMT inhibitor 3 3
Deep brain stimulation 5 4e
Abbreviations: COMT = catechol-O-methyl transferase; MAO = monoamine
oxidase.
a Response to treatment at any time point was reported for 30 of 34 (88.2%)
cases known to have a history of levodopa use. For 14 of 34 (41.2%), de-
velopment of dyskinesia was reported.
b This was classified as good for 22, partial for 5, and unspecified for 1.
c e.g., pramipexole, ropinirole.
d This was classified as good for 8 and partial for 4.
e In one patient, no discharge pattern of the microelectrode recordings
typical for the subthalamic nucleus was seen, nor could a reduction of ri-
gidity be achieved with intraoperative test stimulation. Therefore, no elec-
trodes were implanted.
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Table 3 Comparison of idiopathic and 22q11.2 deletion syndrome–associated Parkinson disease
Idiopathic PDa 22q11.2DS-associated PD
Similarities
Male to female ratio ∼ 2:1 Yes8 Yes (2.5:1)
Cardinal motor symptoms
Bradykinesia, rigidity, and tremors in early-stage
PD
Yes Yes
Asymmetric motor symptoms at onset Yes Yes: ;90% with or without antipsychotic medication
use
Progression of motor symptoms over time Yes Yes
Neuropathologic featuresa
Loss of dopaminergic neurons Yes Yes
Lewy pathology Yes32 2 of 3 reported patients3
Dopaminergic imaging
Reduced striatal DAT/VMAT-2 binding Yes14 Yesb
Good response to levodopa Yes: 70%–100%32 Yes: 93.3%
With development of dyskinesia Yes Yes
New-onset neuropsychiatric symptoms in
the course of PD and its treatment
Yes29 Yes (but see below, Differences)
Differences (potential clinical clues)
Mean age at onset of motor symptoms, y 60.3 ± 12.84 39.2 ± 8.6
Low proportion with EOPD (<45 y) Yes: 5%4 No: 71.4%
Often with first-degree relative affected by PD Yes: 10%–20%33 Maybe less common: 8.9%
Early dystonia No10 Yes: 19.4% in the year of initial presentation ofmotor
symptoms
Developmentof dyskinesiamore common inwomen Yes No: OR = 0.10
Preexisting neuropsychiatric complexityc No Yes: often
Intellectual disability No (population rate ;2.5%) Yes: ;33% (usually mild)34
IQ distribution shifted downward No Yes: ;30 IQ points34
Schizophrenia and other psychotic illnesses No (population rate ;3%) Yes: ;25%11,35
Preexisting antipsychotic medication use No Yes: ;25%
Anxiety, depression Yes (population rate ;10%) Yes: ;20%11
Epilepsy, seizures No (population rate ;1, 2%–5%) Yes: 4%, 16%13
Preexisting motor symptoms of PD No Yes, often (but not always), e.g.:
Dysphagia
Dysphonia
Postural instability
Impaired manual dexterity
Other preexisting nonmotor symptoms of PD No Yes, often (but not always), e.g.:
Hyposmia23
Fatigue (;80%)24
Constipation36
Continued
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Table 3 Comparison of idiopathic and 22q11.2 deletion syndrome–associated Parkinson disease (continued)
Idiopathic PDa 22q11.2DS-associated PD
Preexisting conditions from childhoodc No Yes, often (but not always), e.g.:
Hypernasal speech/velopharyngeal insufficiency
Congenital heart defect (;40%)36
Other congenital anomalies (e.g., scoliosis)
Recurrent infections (e.g., otitis media)
Other preexisting conditions No Hypocalcemia (;80%, often undetected)37
Hypothyroidism (;20%)36
Hearing loss (6%–60%, often undetected)38
Cholelithiasis (;20%)39
Overall considerations
Neurologic assessment may be hindered by the complex neuropsychiatric expression of 22q11.2DS, including intellectual disability
Although young patients with antipsychotic medication and parkinsonism have a low risk of PD in general, in 22q11.2DS the risk is
relatively high
Consider presynaptic dopaminergic imaging for patients with 22q11.2DS with parkinsonism on antipsychotic medication to reduce time to diagnosis,
potentially
Consider consulting a clinician with expertise in 22q11.2DS6
Abbreviations: COMT = catechol-O-methyl transferase; DAT = dopamine transporter; EOPD = early-onset Parkinson disease; MAO = monoamine oxidase;
OR = odds ratio; VMAT-2 = vesicular monoamine transporter 2; 22q11.2DS = 22q11.2 deletion syndrome; PD = Parkinson disease.
aNot investigated in this study.
b Baseline ligand uptake uncertain.16
c Estimated lifetime prevalence of features in 22q11.2DS will vary from patient to patient, depending on age and how cases are ascertained.
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